NAV Lending: The PE Liquidity Tool Every LP Needs to Understand

TL;DR: NAV loans are how PE funds return capital without exiting positions. The mechanics are straightforward. The risks are not. In May 2026, the Financial Stability Board warned that fund-level leverage from NAV facilities is building systemic risk across private credit markets, and most LPs cannot see it coming until it shows up in their distribution notices.

What NAV Lending Actually Is

A NAV loan is a credit facility secured against the net asset value of a private equity fund's portfolio. The fund borrows money. The fund's holdings, stakes in operating companies, serve as collateral. The loan gets repaid when those companies are eventually sold.

Loan-to-value ratios typically run 10-25% of portfolio NAV for buyout funds. Senior secured bank facilities often sit at the lower end, around 10-12% LTV. Unitranche structures from private credit lenders push higher, 15-20%. Credit fund NAV loans are a different animal: those portfolios produce cash interest and trade on secondary markets, so lenders will go to 50-70% LTV.

The typical deal structure: the GP forms a special purpose vehicle (SPV) below the fund level. The SPV pledges interests in the portfolio companies to the lender. The proceeds flow up to the fund. The fund distributes cash to LPs, funds an add-on acquisition, or bridges a capital call. When a portfolio company eventually sells, exit proceeds repay the loan first.

Loan sizes have grown dramatically. Deals that once ran $50-100 million now routinely hit $500 million to $1 billion or more. The overall market sits at roughly $100 billion today, with projections to $350 billion by 2030, according to PitchBook and multiple fund finance advisors.

NAV Loans vs. Subscription Credit Lines

These are completely different products. Subscription credit lines are backed by LP capital commitments. The lender looks at who the LPs are and their legal obligation to fund capital calls. If LPs include major pension funds and endowments, the lender extends credit against those uncalled commitments. The underlying portfolio companies are irrelevant to the credit decision.

NAV facilities flip that logic. The LP capital is already deployed. Commitments are largely drawn. The collateral is what was built with that capital: the portfolio. Sublines are short-term bridge instruments, typically one to three years, used to smooth capital call timing. NAV loans are longer-duration instruments, typically three to six years, used to extract value from mature portfolios that are not ready for exit.

Who Is Lending

The lender roster spans banks and private credit funds.

17Capital is the largest dedicated NAV lender in the world. The firm, backed by Oaktree Capital Management, closed its Credit Fund 2 at $7.5 billion in March 2026, the largest NAV loan fund ever raised. That brings total capital raised by 17Capital to more than $24 billion since 2008. 17Capital has deployed more than $7.5 billion across 30 NAV loans, primarily to established buyout funds in years four through nine of their life cycle.

Goldman Sachs formed a dedicated Capital Solutions Group in 2025, consolidating fund financing, financial sponsor coverage, and alternative asset manager relationships into one unit. Goldman provides both NAV facilities and subscription lines to PE sponsors globally.

JPMorgan has built a NAV loan book spanning dozens of facilities across North America, Europe, and the Middle East. The bank has been exploring synthetic risk transfer transactions to redistribute exposure on its NAV portfolio, allowing JPMorgan to keep loans on balance sheet while managing regulatory capital requirements.

Ares Management and Natixis are also active lenders in this market. Competition among lenders has compressed spreads over the past two years, making NAV facilities cheaper for GPs to access than they were in 2022 and 2023.

Why GPs Are Using NAV Loans Right Now

The exit market froze. That is the core driver.

As of late 2025, more than 30,000 unsold companies sat in global PE portfolios, representing nearly $4 trillion in unrealized value. Median hold times for PE assets still held by GPs reached a record four years. IPO windows opened and closed. Sponsors who raised funds in 2018 and 2019 were staring at year seven and year eight without the exits that drive DPI — distributions to paid-in capital.

LPs noticed. Pension funds, endowments, and sovereign wealth funds depend on PE distributions to fund their own obligations. When cash stops flowing, those institutions feel pressure. GPs who cannot show DPI struggle to raise their next fund.

NAV loans solve that problem without forcing a fire sale. A GP with a portfolio valued at $2 billion can take a 15% LTV loan ($300 million) and distribute it to LPs as if it were exit proceeds. The underlying portfolio stays intact. The GP retains optionality to sell companies when market conditions improve. IRR and DPI metrics improve in the short term.

GPs also use NAV loans to fund add-on acquisitions for existing portfolio companies when the fund's investment period has closed. Without a NAV facility, a fund past its investment period has no dry powder for bolt-on deals. With one, the GP can continue building platform companies.

Why LPs Should Pay Close Attention

Three specific risks matter here.

Hidden leverage. Portfolio companies already carry debt: LBO capital structures typically run five to six times EBITDA. A NAV loan adds a second layer of leverage above that. If a portfolio company defaults, the company's own creditors get paid first. NAV lenders sit behind company-level debt. That structural subordination is significant in a stress scenario. Most LPs reviewing fund-level financials don't see this leverage because it sits at an SPV level below the fund, outside the standard capital account statements.

LPA gaps. Many limited partnership agreements, particularly older ones from 2015 to 2020, are silent on NAV facilities. LPAs often restrict debt at the fund level. But NAV loans are structured at an SPV subsidiary level, below the fund. GPs have argued, sometimes successfully, that those restrictions don't apply. The ILPA issued detailed guidance in 2024 pushing back on that interpretation, but the guidance is not binding.

Recallable distributions. When a GP uses a NAV loan to distribute cash to LPs, those distributions may be recallable if the loan needs to be repaid from LP capital rather than exit proceeds. An LP that already redeployed that cash can face a capital call they didn't expect. That creates cash flow problems and potential tax complications for US taxable investors.

The FSB 2026 Warning

On May 6, 2026, the Financial Stability Board published its first dedicated report on private credit vulnerabilities. The FSB report identified fund-level leverage through NAV facilities as a key data gap and systemic concern. Regulators cannot currently see the full picture of how much leverage sits at the fund level across global PE portfolios.

The FSB report flagged what it called "circles of risk." Banks extend NAV loans to PE funds. Those same banks sell synthetic risk transfer instruments to private credit funds to offload credit exposure. Some of those private credit funds are themselves financed by bank credit lines. The credit risk the bank thought it transferred comes back as counterparty exposure to a fund the bank is also financing.

The FSB also noted that available data captures only $220 billion in direct bank credit lines to private credit funds, while commercial estimates run $270-500 billion. The gap between what regulators can see and what actually exists is large. In early 2026, several private credit funds received redemption requests that exceeded stated withdrawal limits, preceding the FSB's May report.

Red Flags in LP Agreements

Before committing capital to a new fund, read the LPA for these specific items.

Look for any section titled "Fund-Level Borrowing," "Credit Facilities," or "Indebtedness." If the LPA contains explicit language authorizing NAV facilities, the GP has secured permission in advance. That transparency is a positive sign. If the LPA is silent, that silence is a risk. The GP may use NAV facilities later and claim existing borrowing provisions cover them.

Check whether NAV facility debt is counted against the fund's overall leverage cap. ILPA's position is that it should be. Some GPs disagree.

Look for LPAC consent requirements. Does the limited partner advisory committee have to approve NAV facilities? Does it have to approve NAV-funded distributions specifically? ILPA's 2024 guidance recommends that LPAC consent be required before any NAV facility is used to fund LP distributions.

Check disclosure obligations. Does the LPA require the GP to notify all LPs when a NAV facility is put in place? Does it require disclosure of the facility's size, interest rate, covenants, and repayment plan?

Questions to Ask Before Committing

If a GP is raising a new fund and you are evaluating the commitment, ask these questions directly: Does the fund strategy anticipate using NAV facilities? If yes, for what purposes? What is the maximum LTV the GP intends to use? How will NAV facility debt be reported in quarterly and annual LP statements?

Ask whether NAV-funded distributions will be recallable. Ask who the intended lenders are. Ask the GP to confirm that NAV facility debt counts toward the fund's stated leverage cap. Get that in writing in the LPA, not just as verbal assurance during a due diligence call.

NAV lending is a legitimate tool in private equity fund management. It lets GPs manage liquidity across long hold periods without forcing exits at bad prices. Used at conservative LTV ratios with full LP disclosure and LPAC oversight, NAV facilities are no more alarming than any other form of structured finance. The risk is not the product itself. The risk is opacity. LPs who understand the mechanics can ask the right questions, negotiate the right LPA protections, and make informed decisions. According to fund finance practitioners at the 2026 Global Fund Finance Symposium, NAV financing is now mainstream, no longer experimental. The question is not whether a GP uses NAV loans. The question is how, under what governance, and with what disclosure to you as an LP.

Author Disclosure: Jeff Barnes, MBA has no personal position in any company, fund, or platform named in this article. Angel Investors Network has no current commercial relationship with any party mentioned. AIN provides marketing and education services, not investment advice. Past performance does not guarantee future results. All investments involve risk, including loss of principal.